Diligence memo · auto-generated · as of July 2, 2026

SteadMed Medical, LLC

SteadMed Medical, LLC looks under-valued against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

SteadMed Medical, LLC operates in Pharmaceuticals, based in FORT WORTH.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

SteadMed Medical, LLC has raised $3.2M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).

Largest single filing: $3.1M on 2011-03-21.

Most recent recorded round closed around 2011-03-22.

Valuation (modeled)modeled

Provath models SteadMed Medical, LLC at approximately $5.7M (range $113K–$45M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Under-valued. Modeled value is 0.10× the median modeled value of Seed Pharmaceuticals companies in 2010–2012 (58 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Historic cadence: a new round about every 0 months.

Last raise 15.3 yr ago; this sector typically re-raises about every 13 months.

Silent for over 3× the sector's normal cadence.

The last round was 20.5× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 35% of Pharmaceuticals peers (1613 compared).

Modeled value ranks above 10% of those peers.

Closest niche peers: First China Pharmaceutical Group, Inc., MediQuest Holdings LLC, Ampla Pharmaceuticals Inc, Biomimetix Pharmaceutical, Inc., Prexa Pharmaceuticals Inc.

Peoplefiled

3 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.